A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Background: Overexpression of CD123, the alpha subunit of the IL-3 receptor, is characteristic of a number of hematological malignancies, including acute myeloid leukemia (AML), thus providing an attractive candidate for targeted therapeutic approaches in this disease. IMGN632 is a CD123-targeting a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2019-11, Vol.134 (Supplement_1), p.2601-2601
Hauptverfasser:	Daver, Naval G., Erba, Harry P., Papadantonakis, Nikolaos, DeAngelo, Daniel J., Wang, Eunice S., Konopleva, Marina Y, Sloss, Callum M., Wang, Jiuzhou, Malcolm, Kara E., Zweidler-McKay, Patrick A., Kantarjian, Hagop M.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!